Tenaya Therapeutics (NASDAQ:TNYA) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $18.00 target price on the stock.

A number of other research firms have also issued reports on TNYA. Canaccord Genuity Group reissued a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital dropped their target price on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tenaya Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $14.75.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ TNYA opened at $3.29 on Monday. The stock has a market cap of $260.64 million, a P/E ratio of -2.28 and a beta of 2.34. Tenaya Therapeutics has a twelve month low of $1.61 and a twelve month high of $7.01. The stock has a 50 day moving average of $2.09 and a two-hundred day moving average of $2.84.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07. As a group, research analysts predict that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Institutional Trading of Tenaya Therapeutics

A number of institutional investors have recently modified their holdings of the business. Synovus Financial Corp purchased a new position in Tenaya Therapeutics in the third quarter worth $28,000. The Manufacturers Life Insurance Company increased its holdings in shares of Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after purchasing an additional 7,000 shares in the last quarter. Algert Global LLC purchased a new position in shares of Tenaya Therapeutics in the 2nd quarter valued at about $74,000. SG Americas Securities LLC acquired a new stake in shares of Tenaya Therapeutics in the third quarter valued at about $49,000. Finally, XTX Topco Ltd grew its position in Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after buying an additional 16,687 shares during the period. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.